CLASS II Device recall · Reported 13 Jul 2022 · FDA Enforcement Report

Dimension Ctni-In vitro diagnostic test intended recalled

Siemens Healthcare Diagnostics is recalling Dimension Ctni-In vitro diagnostic test intended to quantitively measure cardiac, distributed nationwide in the US. The recall was initiated on 18 May 2022 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesUDI-DI: 00842768013836GA232320221119 Lot Number: GA2323 Exp. Date: 11-19-2022 Recall Extended 9/21/22: UDI: 00842768013836BA308820230329 Lot Number: BA3088 Exp. Date: 2023-03-29
Quantity recalled113 units; Extended: 52 units

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-1341-2022
FDA event ID
90387
Recalling firm
Siemens Healthcare Diagnostics, Newark, DE
Classification
Class II
Status
Terminated
Recall initiated
18 May 2022
FDA classified
6 Jul 2022
Reported
13 Jul 2022
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Other Reasons

Timeline

18 May 2022Recall initiated by company
6 Jul 2022Classified by FDA+49 days
13 Jul 2022Published in enforcement report+7 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Positive bias with Lithium Heparin plasma samples from individuals that are expected to be below the 99th percentile of 0.07 ng/mL [0.07 ¿g/L], may lead to inappropriate intervention for myocardial infarction

Product as listed by the FDA

Dimension CTNI-In vitro diagnostic test intended to quantitively measure cardiac troponin-I levels in human serum and heparinized plasma to aid in the diagnosis of myocardial infarction. Siemens Material Number (SMN)/REF (Catalog Number): 10444905/RF421C

Where it was distributed

Worldwide distribution - US Nationwide distribution in the states of AL, AR, CA, IL MN, MS, NC, ND, NH, OK, SD, TN, TX, WA and the countries of Argentina, Brazil, Canada, France, Germany, India, Mexico, Poland, Portugal, Slovakia, Spain.

Nationwide AlabamaArkansasCaliforniaIllinoisMinnesotaMississippiNorth CarolinaNorth DakotaNew HampshireOklahomaSouth DakotaTennesseeTexasWashington

Questions about this recall

Why was it recalled?

Positive bias with Lithium Heparin plasma samples from individuals that are expected to be below the 99th percentile of 0.07 ng/mL [0.07 ¿g/L], may lead to inappropriate intervention for myocardial infarction

Which lots are affected?

UDI-DI: 00842768013836GA232320221119 Lot Number: GA2323 Exp. Date: 11-19-2022 Recall Extended 9/21/22: UDI: 00842768013836BA308820230329 Lot Number: BA3088 Exp. Date: 2023-03-29

Where was it sold?

Worldwide distribution - US Nationwide distribution in the states of AL, AR, CA, IL MN, MS, NC, ND, NH, OK, SD, TN, TX, WA and the countries of Argentina, Brazil, Canada, France, Germany, India, Mexico, Poland, Portugal, Slovakia, Spain.

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

Other products in this recall event

1 other product · FDA event 90387

This product is part of a recall event; the main page for the event is Dimension LTNI -In vitro diagnostic test intended recalled.

ReportedClassRecallCompanyReasonWhere
CLASS IIDimension LTNI -In vitro diagnostic test intended recalledSiemens Healthcare DiagnosticsOtherNationwide

More recalls from Siemens Healthcare Diagnostics

All 694

Other Test Kits & Diagnostics recalls

All 2,656